Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

Amgen will launch its biosimilar version of Regeneron's blockbuster eye care drug Eylea following a U.S. appeals court ruling ...

A minorities-only study on a dual-action therapy for diabetic macular edema found Hispanic and Latino patients not only ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

Regeneron Pharmaceuticals, Inc. ( NASDAQ:REGN ) shareholders might be concerned after seeing the share price drop ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

Wells Fargo lowered the firm’s price target on Regeneron (REGN) to $1,050 from $1,200 and keeps an Overweight rating on the shares. Given ...

RBC Capital notes that it was announced that the Court of Appeals denied Regeneron’s (REGN) motion for an emergency injunction and the ...

Koss Olinger Consulting LLC increased its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7 ...

Amgen is moving forward with the launch of Pavblu, its biosimilar to Regeneron's blockbuster Eylea, following an appeals ...

Valuation wise, Paradigm Biopharmaceuticals (ASX:PAR) is what Winston Churchill referred to as a riddle wrapped in a mystery ...

Let us look at some big drug/biotech stocks, NVO, NVS, PFE, REGN and BIIB, which are poised to beat on third-quarter earnings ...